The mitochondrial phosphate carrier (PiC) is a mitochondrial solute carrier protein, which is encoded by SLC25A3 in humans. PiC delivers phosphate, a key substrate of oxidative phosphorylation, across the inner mitochondrial membrane. This transport activity is also relevant for allowing effective mitochondrial calcium handling.
Introduction
From measurements of mitochondrial swelling in sucrose or mannitol media, it was recognized very early on that the mitochondrial volume was not freely accessible to even small solutes [1, 2] . By varying the concentration of sucrose, it was further determined that the outer mitochondrial membrane (OMM) was quite permeant (<5 kDa) and that it was the inner mitochondrial membrane (IMM) that provided the barrier to solute movement [3] . Subsequently, and in parallel with studies to sort out oxidative phosphorylation, great efforts were made to understand the transport of solutes across the IMM. Earlier studies had already demonstrated that exogenous inorganic phosphate (Pi) was required to drive oxidative phosphorylation [4, 5] . Clearly, Pi was of importance as an anion whose transport mechanism across the IMM was in need of definition.
Functional characterization of Pi transport in mitochondria
It was again through the use of simple swelling experiments, as well as by measuring mitochondrial respiration in the presence of thiol-reactive mercurial compounds, that Pi transport across the IMM was initially characterized. For swelling experiments, mitochondria were suspended in iso-osmotic solutions containing an anion and a cation (plus EGTA and rotenone); swelling occurred only when both the anion and the cation permeated the mitochondria. Using this method, Chappell and co-workers determined, using NH 4 as the cation, that mitochondria were permeable to Pi and postulated the existence of a carrier system for Pi uptake [2, 6] . At the same time, Fonyo and Bessman [7] sought to understand the basis for the inhibitory action of mercurial compounds on "the energy transfer sequence"; such an inhibition had been described earlier by Lehninger and Boyer [8] [9] [10] . This first study by Fonyo and Bessman, along with followup studies by Fonyo and colleagues and by Tyler, suggested that mercurial compounds suppressed respiration by inhibiting Pi uptake across the IMM [7, 11, 12] . Tyler further demonstrated that exogenous cysteine reverses the inhibitory effect of the mercurial compound, mersalyl, on respiration, and concluded that it was acting on a protein and that the inhibitory effect on respiration was not due to irreversible protein denaturation [12] . Then, using swelling experiments, with inactive respiration and ATP/ADP exchange, mersalyl was shown to prevent the swelling of mitochondria suspended in a solution of ammonium phosphate but not of other permeant ammonium salts [13] . It was subsequently established that H 2 PO 4 -is the transported species [14] , and that it is exchanged for OH -, or taken up in symport with H + ; either way, the uptake of Pi is electroneutral ( Figure 1) . The above studies measured Pi transport indirectly. The first direct measurements of Pi transport kinetics were undertaken by Coty and Pedersen using an "inhibitor-stop" assay which was performed at 0°C, and revealed Pi transport to be extremely rapid [15] . Indeed, the turnover number was estimated to be 50,000 per second at 25°C, which is extremely high among carriers [16] .
Purification of the phosphate transport protein
Hofmann and Kadenbach, using rat liver mitochondria, isolated a candidate Pi transporter that was estimated to be ~31 kDa [17] . Their approach relied in part on the use of mersalyl, which at low concentration did not inhibit Pi transport but protected against irreversible SH reagents [18] . Further studies indicated that the 31 kDa band was in fact multiple bands. Therefore, Durand's group and also Wohlrab refined the above technique by combining radioactive NEM, or mersalyl coupled to an agarose matrix, with hydroxylapatite which, during other purification attempts, was recognized as having a very low affinity for the Pi carrier. This was a more straightforward approach that apparently yielded a single protein band in one case [19] and two bands in another case [20] . In the latter study, the lower molecular weight band was easily confirmed as the adenine nucleotide translocase (ANT) [21] , whereas the higher molecular weight band was identified, by reconstituting the protein into liposomes then measuring 32 P transport, as the Pi carrier. Furthermore, because molecular weight markers were used, the molecular weight of the Pi carrier was revised from ~31 to ~34 kDa.
Kadenbach's group observed that the reconstituted Pi transport activity measured by Wohlrab was very low (maximal rate just below 1 umol/min/mg protein; [20] ).
Subsequently, Pi carrier activity was found to depend on cardiolipin. When purified protein was reconstituted into liposomes, the addition of mitochondrial phospholipids almost doubled the phosphate transport rate [22, 23] . The effect was specific to cardiolipin because other phospholipids, including acidic ones, were ineffective [22] .
Moreover, the activity of recombinant PiC could be increased by more than 5 times by adding ~7% purified cardiolipin to liposomes [24] , decreasing the likelihood of an indirect effect of contaminants in mitochondrial phospholipid preparations. Palmieri used this specific requirement for cardiolipin to attempt to better isolate the Pi carrier [25] ;
indeed, higher resolution SDS gels had revealed multiple bands at ~33-34 kDa, despite the use of hydroxylapatite [26] [27] [28] . Inclusion of cardiolipin in the hydroxylapatite elution buffer largely resolved this issue, and also greatly enhanced protein recovery [25] .
Cloning and molecular characterization of the PiC protein
PiC was first cloned from bovine heart [29] and subsequently, from rat liver [30] and human heart [31] . Further work demonstrated alternatively spliced forms in human and bovine tissues, giving rise to PiC-A and PiC-B isoforms, which show muscle-specific and broad tissue range expression, respectively [32, 33] . Based on the sequence and biochemical evidence, PiC has 6 transmembrane domains and its N and C termini are within the matrix, giving rise to a threefold symmetric organization [29] . It was recognized at the time of the sequencing that PiC is structurally similar to other IMM carrier proteins, the ANT and UCP1 (uncoupling protein 1) [29, 34] . This cohort of IMM proteins is known as mitochondrial carrier (MC) proteins [35, 36] . protein-1) and CREB (-138/-116) [37] .
Role of the PiC in oxidative phosphorylation
Few studies aimed to establish the specific role of the PiC in oxidative phosphorylation.
Rather, it was already understood that exogenous Pi was needed for oxidative phosphorylation, and respiration (both phosphorylating and uncoupled) was used as an outcome measure to study Pi transport across the IMM. However, Fonyo and Ligeti investigated the role of Pi in cation uptake using mersalyl and NEM, and concluded that PiC was an important H + donor for respiration [38] (Figure 1) . A small early onset burst remained in the presence of mersalyl, and this was found to be inhibited by butylmalonate, an inhibitor of the dicarboxylate carrier (DIC) which catalyzes the exchange of dicarboxylic acids (e.g., malate or succinate) for Pi [39] . It was concluded that both the PiC and the DIC have the possibility to support cation-stimulated respiration [40] .
The functional importance of the PiC was first demonstrated in yeast (S. cerevisiae) that exhibited delayed growth or failed to grow on non-fermentable substrate when deleted for MIR1, the yeast homologue of PiC [41] or for MIR1 and PIC2 [42] , respectively. PIC2 encodes a second mitochondrial Pi carrier in yeast and also in Arabidopsis thaliana, shares 40% homology to mir1, and appears to play a role under certain stress conditions [43] . That these yeast mutants fail to thrive specifically when grown in the presence of mitochondrial substrates suggests the relevance of the yeast homologs of the PiC for oxidative phosphorylation. It is only very recently that the role of the PiC in ATP production and oxidative phosphorylation has been confirmed in mammals. This was achieved using mouse models of PiC depletion [44, 45] and by studying a loss-offunction mutation in the human SLC25A3 gene [42] (see below). 
Role of PiC in calcium handling
The highly negative inner membrane potential ( m ) presents a robust driving force for mitochondrial Ca 2+ uptake. Ca 2+ uptake occurs as uniport and is mediated by the mitochondrial calcium uniporter (mtCU) across the IMM (Figure 1) . The mtCU is a highly Ca 2+ selective ion channel formed by oligomers of pore forming MCU proteins and regulatory proteins (Figure 1) Pi uptake can also be mediated by the DIC and the ATP-Mg/Pi carriers [39, 62] (Figure   1 ) but the primary pathway likely is provided by the PiC [40] ; however, this evidence rests on potentially non-specific reagents such as NEM and mersalyl. Notably, PiC has also been proposed to undergo a Ca 2+ -induced cyclophilin D (CyPD)-mediated conformational change providing a mechanism central to the opening of the PTP [63] .
However, a requirement for PiC in PTP opening remains debated [44, 64] .
In summary, Pi transport-mediated control of mitochondrial Ca 2+ handling has been well established and circumstantial evidence supports a major role for PiC in this paradigm.
The high turnover rate of the PiC is an advantage to enable Pi to effectively buffer Ca 2+ that enters at a high rate through an ion channel. The next section describes genetic strategies that have been developed to address more directly the role of PiC in PTP opening and calcium handling in murine models [44, 45] .
Slc25a3 mouse phenotypes
Recently, the Baines and Molkentin groups have produced mice with both elevated and decreased cardiac expression of PiC. The two transgenic lines showed ~5 fold expression of PiC without a significant change in ANT and ATP synthase proteins, cardiac size and function [44] . Mitochondria isolated from the transgenic hearts showed unaltered respiration, ATP level, Ca 2+ retention and activation of the PTP.
In the first set of complementing studies, shRNA was used to attain ~60% reduction in cardiac PiC protein abundance without altering ANT and ATP synthase [44] . The heart showed hypertrophy and slightly decreased fractional shortening. Mitochondrial respiration and Ca 2+ retention were unaltered but the steady-state ATP level was decreased. In parallel studies, inducible and cardiac-specific deletion of PiC was established [45] . In this model, drug-induction resulted in >90% decrease in PiC protein, whereas other respiratory chain proteins were unaltered. Similar to the shRNAmediated PiC silencing, cardiac hypertrophy was observed though cardiac shortening remained unaffected. Strikingly, time-dependent mitochondrial phosphate uptake was eliminated and the mitochondrial ATP level was decreased but Ca 2+ retention was not impaired and was in fact increased.
The lack of a phenotype for the PiC transgenic mouse likely indicates that the abundance of PiC does not limit the transport and potential other functions of PiC in mouse heart, which is in accordance with the exceptionally high turnover high turnover rate of the PiC. The cardiac hypertrophy and energy deficit observed upon PiC depletion is in line with the phenotype of the ANT knockout mouse, in which another component of the ATP synthasome is missing [65] . Thus, a major reason for the phenotype can be insufficient Pi transport and oxidative phosphorylation. Although PiC has been shown to interact with CyPD, a regulator of the PTP, the lack of a change in PTP activation in the PiC deficient mitochondria is not unexpected because CyPD as a chaperone also interacts with several proteins unrelated to the PTP. Perhaps the most surprising finding is that PiC-deficient mitochondria are competent to take up Ca 2+ and Ca 2+ uptake happens without greater expansion of the matrix. Although the DIC and the ATP-Mg/Pi carriers could provide surrogate phosphate uptake pathways, no timedependent mitochondrial Pi uptake was documented in this study [45] . Since Pi uptake was not measured during Ca 2+ uptake, a possibility remains that Ca 2+ -stimulated Pi uptake also occurred in the mitochondria lacking PiC.
Pathogenic mutations in the human PIC gene
The first disease-associated PiC mutations were described in 2007. Two different mutations that affect only exon 3A and therefore the PiC-A isoform [42, 66, 67] were first observed in two different families of Turkish origin [42, 66] . More recently, one of these mutations (c.215G>A) was found in a third Turkish family (Mayr J.A. et al, unpublished). Remarkably the c.158-9A>G mutation, which results in a gain of a spliceacceptor, was also reported in a family of Guatemalan origin [67] , suggesting that at least this mutation has a widespread prevalence. Furthermore, mutations in regions outside of exon 3 have also been described, which affect both PiC-A and B isoforms [67] . Every patient presented mainly with cardiomyopathy regardless of the involvement of only the A or A and B isoforms. Elevated lactate and skeletal myopathy were also displayed by every patient of PiC-A specific mutation. The prevalence of pathogenic PiC mutations may be significantly underestimated because the cardiac impairments can be fatal early after birth, or can mimic other forms of hypertrophic cardiomyopathy.
Furthermore, symptoms may not be distinct enough to suggest a PiC dysfunction. One remarkable feature common to patients with SLC25A3 mutations is the lack of neurocognitive involvement, when compared to other mitochondrial disorders causing cardiomyopathy [66, 67] .
The major difference in the symptoms associated with the PiC-A mutations compared to those associated with the mutations affecting both isoforms (see Table 1 ) might be explained by several factors, including tissue specific expression and distinct enzymatic activity of each isoform. The predominant involvement of cardiac and skeletal muscle in mitochondrial PiC deficiency can be explained by tissue specific isoforms of the enzyme, which are formed by tissue specific alternative splicing. It is also known that the transport affinity for Pi of PiC-A is 3-fold higher than that of PiC-B, whereas the maximal transport rate of PiC-B is 3-fold higher compared to PiC-A [24] . However, it is unknown how tissue function is affected by changes in the ratio of these two isoforms [67] .
Another intriguing aspect of the human PiC mutations is that they appear to be at least partially functionally compensated to allow survival despite a severe clinical situation during infancy. Similar compensation has also been documented in Barth syndrome [68] and in TMEM70 deficiency [69] , which, like PiC deficiency, are primary mitochondrial diseases caused by mutations in nuclear-encoded genes. These diseases also manifest as life threatening diseases during early infancy but show a stabilization or even improvement of the cardiac impairment if patients survive the first years of life. Thus PiC deficiency is not the only primary mitochondrial disease with a severe clinical presentation during infancy but with some surviving adults. The compensatory mechanisms have not been identified for PiC or for these other deficiencies. In a skeletal muscle biopsy from one of the surviving individuals harboring a pathological PiC-A variant, there was evidence for elevated mitochondrial biogenesis [66] . However, this alone would be unlikely to compensate for PiC-A deficiency. In this same individual, there was essentially no PiC protein evident on a western blot, and there was only a very low signal on immunohistochemistry. Since the antibody that was used detects both isoforms, no or only a small compensatory increase in PiC-B protein occurred [66] .
It is more likely that, in this individual, functional compensation has been achieved by the alteration of one or more metabolic pathways. An upregulation of glycolytic ATP production is one possibility. But there are, at least theoretically, other less obvious candidates, such as increased PiC transport through the DIC. This possibility has not been formally tested. Even the entry of modest amounts of Pi into mitochondria could be beneficial. For example, a decreased level of Pi could continue to support the phosphorylation of ADP. This could prevent a large depolarization with consequent mitochondrial ATP consumption [58] ; such a mechanism would spare cytosolic ATP pools. Interestingly, in yeast, destabilization of the ATP synthase was compensated by ATP production via substrate level phosphorylation of ADP within mitochondria [70] , demonstrating that this type of metabolic reconfiguration can arise in an intact organism.
Future directions
The basic biophysical and molecular characteristics of mitochondrial Pi transport and the PiC were established many years ago. Yet, the questions, and even surprises, that arise from the more recently discovered human PiC mutations and the PiC mouse models bring fresh relevance to the study of the PiC. The clinical picture of individuals with PiC mutations raises new and fundamental questions about the relationship between the A and B isoforms, the basis for the healthy survival of some of affected individuals, and the lack of neurological symptoms despite severe cardiomyopathy due to mutations affecting both isoforms. Indeed, while the mutations affecting both isoforms are predicted to be pathogenic, a more complete understanding of these mutations is needed. Regarding Ca 2+ , its effective mitochondrial uptake in the mouse model, with almost complete depletion of both isoforms, is surprising [45] . Therefore, the precise role of the PiC in mitochondrial Ca 2+ uptake requires further investigation. Since Pi likely is a primary factor in mitochondrial matrix Ca 2+ buffering that shows remarkable adaptive changes during both acute and prolonged increases in mitochondrial Ca 2+ uptake [53, 59] 
